Australia's Amplia Therapeutics rises on FDA nod for cancer drug trial
** Shares of Amplia Therapeutics ATX.AX rise as much as
1.3% to A$0.081, their highest since Jan. 5
** Drug developer says it has received US FDA clearance for
clinical trial of its Investigational New Drug application for
pancreatic cancer
** About 162,900 shares change hands, compared with the
30-day average volume of 23,835
(Reporting by Neha Soni in Bengaluru)
((Neha.Soni@thomsonreuters.com))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement